Tim-3 and Tim-4 as the potential targets for antitumor therapy

References

• McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, Freeman GJ, Umetsu DT, DeKruyff RH. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nature immunology 2001; 2:1109-16; PMID:11725301; http://dx.doi.org/10.1038/ni739
   PubMed Web of Science ®Google Scholar
• Li Z, Ju Z, Frieri M. The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity. Allergy and asthma proceedings : the official journal of regional and state allergy societies 2013; 34:e21-6; PMID:23406933; http://dx.doi.org/10.2500/aap.2013.34.3646
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunological reviews 2010; 235:172-89; PMID:20536563
   PubMed Web of Science ®Google Scholar
• Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nature immunology 2012; 13:832-42; PMID:22842346; http://dx.doi.org/10.1038/ni.2376
   PubMed Web of Science ®Google Scholar
• Tang D, Lotze MT. Tumor immunity times out: TIM-3 and HMGB1. Nature immunology 2012; 13:808-10; PMID:22910384; http://dx.doi.org/10.1038/ni.2396
   PubMed Web of Science ®Google Scholar
• Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen BS, Melum E, Pertel T, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 2015; 517:386-90; PMID:25363763; http://dx.doi.org/10.1038/nature13848
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Karisola P, Pena-Cruz V, Dorfman DM, Jinushi M, Umetsu SE, Butte MJ, Nagumo H, Chernova I, Zhu B, et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 2007; 27:927-40; PMID:18082433; http://dx.doi.org/10.1016/j.immuni.2007.11.011
   PubMed Web of Science ®Google Scholar
• Rodriguez-Manzanet R, Sanjuan MA, Wu HY, Quintana FJ, Xiao S, Anderson AC, Weiner HL, Green DR, Kuchroo VK. T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2010; 107:8706-11; PMID:20368430; http://dx.doi.org/10.1073/pnas.0910359107
   PubMed Web of Science ®Google Scholar
• Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4 as a phosphatidylserine receptor. Nature 2007; 450:435-9; PMID:17960135; http://dx.doi.org/10.1038/nature06307
   PubMed Web of Science ®Google Scholar
• Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Current opinion in immunology 2012; 24:213-6; PMID:22226204; http://dx.doi.org/10.1016/j.coi.2011.12.005
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell stem cell 2010; 7:708-17; PMID:21112565; http://dx.doi.org/10.1016/j.stem.2010.11.014
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Akashi K. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. Annals of the New York Academy of Sciences 2012; 1266:118-23; PMID:22901263; http://dx.doi.org/10.1111/j.1749-6632.2012.06550.x
   PubMed Web of Science ®Google Scholar
• Kikushige Y, Miyamoto T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells. International journal of hematology 2013; 98:627-33; PMID:24046178; http://dx.doi.org/10.1007/s12185-013-1433-6
   PubMed Web of Science ®Google Scholar
• Baghdadi M, Yoneda A, Yamashina T, Nagao H, Komohara Y, Nagai S, Akiba H, Foretz M, Yoshiyama H, Kinoshita I, et al. TIM-4 glycoprotein-mediated degradation of dying tumor cells by autophagy leads to reduced antigen presentation and increased immune tolerance. Immunity 2013; 39:1070-81; PMID:24315994; http://dx.doi.org/10.1016/j.immuni.2013.09.014
   PubMed Web of Science ®Google Scholar
• Ramello MC, Boari JT, Canale FP, Mena HA, Negrotto S, Gastman B, Gruppi A, Rodriguez EV, Montes CL. Tumor-induced senescent T cells promote the secretion of pro-inflammatory cytokines and angiogenic factors by human monocytes/macrophages through a mechanism that involves Tim-3 and CD40L. Cell death & disease 2014; 5:e1507; PMID:25375372; http://dx.doi.org/10.1038/cddis.2014.451
   PubMedGoogle Scholar
• Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V, Zarour HM. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. The Journal of experimental medicine 2010; 207:2175-86; PMID:20819923; http://dx.doi.org/10.1084/jem.20100637
   PubMed Web of Science ®Google Scholar
• Arai Y, Saito H, Ikeguchi M. Upregulation of TIM-3 and PD-1 on CD4+ and CD8+ T Cells Associated with Dysfunction of Cell-Mediated Immunity after Colorectal Cancer Operation. Yonago acta medica 2012; 55:1-9; PMID:24031134
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. The Journal of experimental medicine 2010; 207:2187-94; PMID:20819927; http://dx.doi.org/10.1084/jem.20100643
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer research 2014; 74:1045-55; PMID:24343228; http://dx.doi.org/10.1158/0008-5472.CAN-13-2908
   PubMed Web of Science ®Google Scholar
• Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, Zhang S. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. Journal of translational medicine 2013; 11:215; PMID:24044888; http://dx.doi.org/10.1186/1479-5876-11-215
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer research 2012; 72:917-27; PMID:22186141; http://dx.doi.org/10.1158/0008-5472.CAN-11-1620
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer research 2012; 72:887-96; PMID:22205715; http://dx.doi.org/10.1158/0008-5472.CAN-11-2637
   PubMed Web of Science ®Google Scholar
• Yan W, Liu X, Ma H, Zhang H, Song X, Gao L, Liang X, Ma C. Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages. Gut 2015
   Web of Science ®Google Scholar
• Flecken T, Sarobe P. Tim-3 expression in tumour-associated macrophages: a new player in HCC progression. Gut 2015; PMID:25694141
   PubMed Web of Science ®Google Scholar
• Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nature reviews Clinical oncology 2011; 8:528-39; PMID:21587219; http://dx.doi.org/10.1038/nrclinonc.2011.71
   PubMed Web of Science ®Google Scholar
• Qadir MA, Kwok B, Dragowska WH, To KH, Le D, Bally MB, Gorski SM. Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast cancer research and treatment 2008; 112:389-403; PMID:18172760; http://dx.doi.org/10.1007/s10549-007-9873-4
   PubMed Web of Science ®Google Scholar
• Carew JS, Medina EC, Esquivel JA, 2nd, Mahalingam D, Swords R, Kelly K, Zhang H, Huang P, Mita AC, Mita MM, et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. Journal of cellular and molecular medicine 2010; 14:2448-59; PMID:19583815; http://dx.doi.org/10.1111/j.1582-4934.2009.00832.x
   PubMed Web of Science ®Google Scholar
• Apel A, Herr I, Schwarz H, Rodemann HP, Mayer A. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer research 2008; 68:1485-94; PMID:18316613; http://dx.doi.org/10.1158/0008-5472.CAN-07-0562
   PubMed Web of Science ®Google Scholar
• Baghdadi M, Nagao H, Yoshiyama H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer immunology, immunotherapy : CII 2013; 62:629-37; PMID:23143694; http://dx.doi.org/10.1007/s00262-012-1371-9
   PubMed Web of Science ®Google Scholar
• Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, Verneris MR, Cichocki F, Holman CJ, Panoskaltsis-Mortari A, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012; 119:3064-72; PMID:22323453; http://dx.doi.org/10.1182/blood-2011-06-360321
   PubMed Web of Science ®Google Scholar
• Ndhlovu LC, Lopez-Verges S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, Lanier LL. Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 2012; 119:3734-43; PMID:22383801; http://dx.doi.org/10.1182/blood-2011-11-392951
   PubMed Web of Science ®Google Scholar
• da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, Bhardwaj N. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer immunology research 2014; 2:410-22; PMID:24795354; http://dx.doi.org/10.1158/2326-6066.CIR-13-0171
   PubMed Web of Science ®Google Scholar
• Jajosky AN, Coad JE, Vos JA, Martin KH, Senft JR, Wenger SL, Gibson LF. RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression. Stem cells translational medicine 2014; 3:836-48; PMID:24855276; http://dx.doi.org/10.5966/sctm.2013-0193
   PubMedGoogle Scholar
• Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia Z, Wang YP, Suo J, Cao X. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PloS one 2013; 8:e81799; PMID:24339967; http://dx.doi.org/10.1371/journal.pone.0081799
   PubMed Web of Science ®Google Scholar
• Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, Zhang X, Ma C. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. American journal of clinical pathology 2012; 137:978-85; PMID:22586058; http://dx.doi.org/10.1309/AJCP9Q6OVLVSHTMY
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhou X, Huang X, Li Q, Gao L, Jiang L, Huang M, Zhou J. Tim-3 expression in cervical cancer promotes tumor metastasis. PloS one 2013; 8:e53834; PMID:23335978; http://dx.doi.org/10.1371/journal.pone.0053834
   PubMed Web of Science ®Google Scholar
• Wu J, Liu C, Qian S, Hou H. The expression of Tim-3 in peripheral blood of ovarian cancer. DNA and cell biology 2013; 32:648-53; PMID:24007284; http://dx.doi.org/10.1089/dna.2013.2116
   PubMed Web of Science ®Google Scholar
• Piao YR, Piao LZ, Zhu LH, Jin ZH, Dong XZ. Prognostic value of T cell immunoglobulin mucin-3 in prostate cancer. Asian Pacific journal of cancer prevention : APJCP 2013; 14:3897-901; PMID:23886204; http://dx.doi.org/10.7314/APJCP.2013.14.6.3897
   PubMed Web of Science ®Google Scholar
• Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012; 56:1342-51; PMID:22505239; http://dx.doi.org/10.1002/hep.25777
   PubMed Web of Science ®Google Scholar
• Bai J, Li X, Tong D, Shi W, Song H, Li Q. T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2013; 34:805-9; PMID:23359271; http://dx.doi.org/10.1007/s13277-012-0610-1
   PubMed Web of Science ®Google Scholar
• Tong D, Zhou Y, Chen W, Deng Y, Li L, Jia Z, Qi D. T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer. Molecular biology reports 2012; 39:9941-6; PMID:22733499; http://dx.doi.org/10.1007/s11033-012-1862-y
   PubMed Web of Science ®Google Scholar
• Cai C, Wang L, Wu Z, Li M, Chen W, Sun Y. T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and renal cell carcinoma. DNA and cell biology 2012; 31:1285-9; PMID:22472081; http://dx.doi.org/10.1089/dna.2012.1625
   PubMed Web of Science ®Google Scholar
• Li Z, Li N, Zhu Q, Zhang G, Han Q, Zhang P, Xun M, Wang Y, Zeng X, Yang C, et al. Genetic variations of PD1 and TIM3 are differentially and interactively associated with the development of cirrhosis and HCC in patients with chronic HBV infection. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2013; 14:240-6; PMID:23291409; http://dx.doi.org/10.1016/j.meegid.2012.12.008
   PubMed Web of Science ®Google Scholar
• Cao B, Zhu L, Zhu S, Li D, Zhang C, Xu C, Zhang S. Genetic variations and haplotypes in TIM-3 gene and the risk of gastric cancer. Cancer immunology, immunotherapy : CII 2010; 59:1851-7; PMID:20811886; http://dx.doi.org/10.1007/s00262-010-0910-5
   PubMed Web of Science ®Google Scholar